Cross-clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations by Illumina MiSeq

BACKGROUND: Viral resistance to antiretroviral therapy threatens our best methods to control and prevent HIV infection. Current drug resistance genotyping methods are costly, optimized for subtype B virus, and primarily detect resistance mutations to protease and reverse transcriptase inhibitors. Wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Dudley, Dawn M, Bailey, Adam L, Mehta, Shruti H, Hughes, Austin L, Kirk, Gregory D, Westergaard, Ryan P, O’Connor, David H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302432/
https://www.ncbi.nlm.nih.gov/pubmed/25533166
http://dx.doi.org/10.1186/s12977-014-0122-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302432/
https://www.ncbi.nlm.nih.gov/pubmed/25533166
http://dx.doi.org/10.1186/s12977-014-0122-8

Ejemplares similares